RA Capital Management 13F holdings, Q2 2018
Holdings as of June 30, 2018 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 27 US equity positions worth $1.5bn in its Q2 2018 13F filing. The largest position was WVE at 18.7% of the reported book, followed by ASND and SLDB. Against the Q1 2018 filing, it opened 4 new positions, added to 4 and reduced 1 among the top 27 holdings.
What did RA Capital Management own in Q2 2018? Top 27 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2018 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 18.7% | $287.3m | 7,512,049 | 0% | held |
| 2 | ASND ASCENDIS PHARMA A S | Healthcare | 18.3% | $282.1m | 4,240,536 | 0% | held |
| 3 | SLDB SOLID BIOSCIENCES INC | 6.2% | $95.8m | 2,689,444 | 0% | held | |
| 4 | ENDOCYTE INC | 5.1% | $78.0m | 5,649,884 | 46% | added | |
| 5 | MNTA MOMENTA PHARMACEUTICALS INC | 4.9% | $75.7m | 3,702,533 | – | new | |
| 6 | IMMU IMMUNOMEDICS INC | 4.8% | $73.8m | 3,119,778 | – | new | |
| 7 | MYOVANT SCIENCES LTD | 4.2% | $64.7m | 2,830,455 | 0% | held | |
| 8 | INFLARX NV | 4.1% | $63.4m | 1,967,148 | 21% | added | |
| 9 | TGTX TG THERAPEUTICS INC | Healthcare | 3.7% | $56.3m | 4,278,796 | 73% | added |
| 10 | SG7 SAGE THERAPEUTICS INC | 3.6% | $54.9m | 350,933 | -1% | reduced | |
| 11 | ZOGENIX INC | 3.3% | $50.6m | 1,145,268 | 0% | held | |
| 12 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.1% | $48.2m | 1,541,743 | – | new |
| 13 | DICERNA PHARMACEUTICALS INC | 3.1% | $48.2m | 3,933,489 | 0% | held | |
| 14 | EIDOS THERAPEUTICS INC | 2.9% | $44.0m | 2,162,671 | – | new | |
| 15 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 2.6% | $40.0m | 6,984,692 | 0% | held |
| 16 | RA PHARMACEUTICALS INC | 2.5% | $38.3m | 3,851,808 | 0% | held | |
| 17 | KALA PHARMACEUTICALS INC | 1.9% | $29.0m | 2,113,236 | 0% | held | |
| 18 | APELLIS PHARMACEUTICALS INC | 1.3% | $19.8m | 900,000 | 0% | held | |
| 19 | CLEARSIDE BIOMEDICAL INC | 1.1% | $16.3m | 1,525,000 | 0% | held | |
| 20 | SCPHARMACEUTICALS INC | 1.0% | $16.2m | 2,857,143 | 0% | held | |
| 21 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.9% | $14.4m | 1,121,153 | 70% | added |
| 22 | 4XC1 KALVISTA PHARMACEUTICALS INC | 0.8% | $11.7m | 1,441,070 | 0% | held | |
| 23 | AVEO PHARMACEUTICALS INC | 0.7% | $11.4m | 5,062,759 | 0% | held | |
| 24 | SPRO SPERO THERAPEUTICS INC | Healthcare | 0.7% | $10.9m | 741,647 | 0% | held |
| 25 | GLYCOMIMETICS INC | 0.3% | $4.1m | 253,547 | 0% | held | |
| 26 | PROTEON THERAPEUTICS INC | 0.2% | $3.3m | 1,337,462 | 0% | held | |
| 27 | G1 THERAPEUTICS INC | 0.1% | $1.7m | 40,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.